Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649–58.

Article  CAS  PubMed  Google Scholar 

Soliman NA, Nabhan MM, Abdelrahman SM, et al. Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center. Nephrol Ther. 2017;13(3):176–82.

Article  PubMed  PubMed Central  Google Scholar 

Ariceta G, Barrios K, Brown BD, et al. Hepatic lactate dehydrogenase A: an RNA interference target for the treatment of all known types of primary hyperoxaluria. Kidney Int Rep. 2021;6(4):1088–98.

Article  PubMed  PubMed Central  Google Scholar 

Lai C, Pursell N, Gierut J, et al. Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria. Mol Ther. 2018;26(8):1983–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forbes TA, Brown BD, Lai C. Therapeutic RNA interference: a novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2022;88(6):2525–38.

Article  CAS  PubMed  Google Scholar 

Dicerna Pharmaceuticals. RNAi therapies to target the cause of disease. 2021. https://dicerna.com/. Accessed 9 Nov 2023.

Novo Nordisk. RIVFLOZATM (nedosiran) injection, for subcutaneous use: US prescribing information. 2023. https://www.fda.gov/. Accessed 9 Nov 2023.

Novo Nordisk. FDA approves Rivfloza™ for children ≥ 9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition [media release]. 2 Oct 2023. https://www.novonordisk.com/.

Bacchetta J, Lieske JC. Primary hyperoxaluria type 1: novel therapies at a glance. Clin Kidney J. 2022;15(Suppl 1):i17–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novo AS. Novo Nordisk announces completion of Dicerna Pharmaceuticals acquisition [media release]. 28 Dec 2021. http://www.novonordisk.com.

Dicerna Pharmaceuticals, Alnylam Pharmaceuticals. Alnylam and Dicerna form RNAi therapeutics collaboration on alpha-1 antitrypsin deficiency-associated liver disease and complete cross-license agreement for primary hyperoxaluria programs [media release]. 6 Apr 2020. http://www.dicerna.com.

Liu A, Zhao J, Shah M, et al. Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: design, development, and clinical studies. ACS Pharmacol Transl Sci. 2022;5(11):1007–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldfarb DS, Lieske JC, Groothoff J, et al. Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). Urolithiasis. 2023;51(1):80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amrite A, Fuentes E, Marbury TC, et al. Safety, pharmacokinetics, and exposure-response modeling of nedosiran in participants with severe chronic kidney disease. Clin Pharmacol Drug Dev. 2023. https://doi.org/10.1002/cpdd.1320.

Article  PubMed  Google Scholar 

Baum MA, Langman C, Cochat P, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2023;103(1):207–17.

Article  CAS  PubMed  Google Scholar 

Hoppe B, Koch A, Cochat P, et al. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 2022;101(3):626–34.

Article  CAS  PubMed  Google Scholar 

Hoppe B, Coenen M, Schalk G, et al. Nedosiran in primary hyperoxaluria subtype 1: interim results from an open-label extension trial (PHYOX3) [abstract no. P1-050]. Pediatr Nephrol. 2023;38(7):2289.

Google Scholar 

Hoppe B, Coenen M, Schalk G, et al. PHYOX3: a long-term, open-label extension trial of nedosiran in patients with primary hyperoxaluria type 1, 2, or 3 [abstract no. PO1625 plus poster]. J Am Soc Nephrol. 2020;31(Suppl):515.

Google Scholar 

Groothoff J, Sellier-Leclerc AL, Deesker L, et al. Long-term nedosiran safety and efficacy in primary hyperoxaluria type 1 (PH1): interim analysis of PHYOX3 [abstract no. TH-PO1128]. In: American Society of Nephrology Kidney Week. 2023.

Goldfarb DS, Groothoff J, Vrhnjak B. Nedosiran in patients with primary hyperoxaluria 3: interim results from an ongoing open label, safety extension trial (PHYOX3) [poster]. In: 14th International Hyperoxaluria Workshop. 2023.